Atara Biotherapeutics (ATRA) Investor Presentation - Slideshow

Tab-cel® Program - Atara is working towards completing the BLA submission for Tab-cel® in Q3 2021, pending alignment with the FDA [12], with potential for the first allogeneic T-cell immunotherapy on the market in 2022 [12] - Tab-cel® achieved a 50% objective response rate (ORR) in the pivotal Phase 3 study interim analysis by Independent Oncologic and Radiographic Assessment (IORA) for EBV+ PTLD patients who failed rituximab [36] - In Phase 2 and EAP studies, Tab-cel® showed 83% overall survival at 2 years in responders and 79% overall survival at 2 years for all patients [33] - The company estimates that there are several hundred EBV+ PTLD patients in the U S who have failed rituximab ± chemo, representing a high unmet medical need [40] ATA188 Program - Data from the open-label clinical dataset suggests transformative potential in MS, and disability improvement data from the RCT has the potential to unlock a multi-billion dollar opportunity [12] - Phase 1 data in Progressive MS showed 50% sustained disability improvement (SDI) in Cohorts 3 – 4 at 15 months [64] - The estimated US market forecast for Progressive MS in 2025 is a multi-billion dollar opportunity, with each 10% of market share representing approximately $750 million to $1 billion in revenue [83] CAR T Program - Atara has a technologically differentiated portfolio of high-potential, preclinical CAR T assets, with multiple programs showing clinical data in both liquid and solid tumors [12] - Atara entered into a strategic collaboration with Bayer to develop Atara's mesothelin CAR T program (ATA3271) and autologous program (ATA2271), receiving $60 million upfront and eligible for up to $610 million in milestone payments, plus tiered royalties up to low double-digit percentage of net sales [87] Financial Status - Atara is well-capitalized with a planned cash runway into 2023 [25] - The company had 84 1 million shares outstanding as of March 31, 2021 [25] and net cash used in operating activities in Q1 2021 was $65 7 million [25]